Thrifty, Here is a note from an AIDS conference
Post# of 153872
(Total Views: 673)
Posted On: 10/28/2020 4:19:09 PM
Re: thriftycents #63572
Thrifty,
Here is a note from an AIDS conference in 2005, addressing the concern that allosteric/small molecule inhibition of CCR5, especially in conjunction with antivirals (Remdesivir anyone), causes hepatotoxicity.
Obviously leronlimab has proven itself to be in a safety class by itself.
https://www.natap.org/2005/EACS/eacs_5.htm
Is Liver Toxicity a CCR5 Antagonist Class Effect? 2NN & Hepatoxicity; D.A.D. study & liver related death; Liver toxicity & HIV, Italian study
"All transaminase elevations vanished spontaneously when people stopped maraviroc and the PIs. Tipranavir/ritonavir can certainly pummel the liver in people with HIV, and liver toxicity did not arise with maraviroc plus placebo. So this study cannot pin the liver enzyme blips on maraviroc.
Still, no one can be happy about the unpropitious proportion of ALT or AST leaps in these healthy people, 42% Grade 1 or 2 "events" may not seem troubling, but these healthy people took maraviroc and tipranavir/ritonavir for only 8 days. In the red-alert case from the aplaviroc trial, liver enzymes looked just fine for 58 days.
Even if maraviroc didn't stir up liver enzymes all by itself—as aplaviroc did—a drug that compounds liver toxicity from other antiretrovirals would have a more limited salvage role or—at a minimum—would require tight monitoring."
Here is a note from an AIDS conference in 2005, addressing the concern that allosteric/small molecule inhibition of CCR5, especially in conjunction with antivirals (Remdesivir anyone), causes hepatotoxicity.
Obviously leronlimab has proven itself to be in a safety class by itself.
https://www.natap.org/2005/EACS/eacs_5.htm
Is Liver Toxicity a CCR5 Antagonist Class Effect? 2NN & Hepatoxicity; D.A.D. study & liver related death; Liver toxicity & HIV, Italian study
"All transaminase elevations vanished spontaneously when people stopped maraviroc and the PIs. Tipranavir/ritonavir can certainly pummel the liver in people with HIV, and liver toxicity did not arise with maraviroc plus placebo. So this study cannot pin the liver enzyme blips on maraviroc.
Still, no one can be happy about the unpropitious proportion of ALT or AST leaps in these healthy people, 42% Grade 1 or 2 "events" may not seem troubling, but these healthy people took maraviroc and tipranavir/ritonavir for only 8 days. In the red-alert case from the aplaviroc trial, liver enzymes looked just fine for 58 days.
Even if maraviroc didn't stir up liver enzymes all by itself—as aplaviroc did—a drug that compounds liver toxicity from other antiretrovirals would have a more limited salvage role or—at a minimum—would require tight monitoring."
(3)
(0)